Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310)

John C. Byrd; Stephen Smith; Nina Wagner-Johnston; Jeff Sharman; Andy I. Chen; Ranjana Advani; Bradley Augustson; Paula Marlton; S. Renee Commerford; Kwame Okrah; Lichuan Liu; Elaine Murray; Elicia Penuel; Ashley F. Ward; Ian W. Flinn

doi:10.18632/oncotarget.27011

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310)

John C. Byrd, Stephen Smith, Nina Wagner-Johnston, Jeff Sharman, Andy I. Chen, Ranjana Advani, Bradley Augustson, Paula Marlton, S. Renee Commerford, Kwame Okrah, Lichuan Liu, Elaine Murray, Elicia Penuel, Ashley F. Ward, Ian W. Flinn

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

This article has been corrected: Due to errors in figure preparation, the data for Table 3 was listed incorrectly. It has now been updated with corrected numbers (see text in Table 3) and the resulting graphs (Figure 2A and 2B) have been updated as well. In addition, the reference list for this paper was accidentally alphabetized during the production process, while citation numbers within the article remained according to first-mention. In this correction, the entire references list has been corrected. We include the reference list in their order of mention so that the citation number in the article corresponds to the reference number in the list.(Table Persented).

Original language	English (US)
Pages (from-to)	3827-3830
Number of pages	4
Journal	Oncotarget
Volume	10
Issue number	38
DOIs	https://doi.org/10.18632/oncotarget.27011
State	Published - 2019

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/oncotarget.27011

Cite this

Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., Augustson, B., Marlton, P., Renee Commerford, S., Okrah, K., Liu, L., Murray, E., Penuel, E., Ward, A. F., & Flinn, I. W. (2019). Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310). Oncotarget, 10(38), 3827-3830. https://doi.org/10.18632/oncotarget.27011

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310). / Byrd, John C.; Smith, Stephen; Wagner-Johnston, Nina et al.
In: Oncotarget, Vol. 10, No. 38, 2019, p. 3827-3830.

Research output: Contribution to journal › Comment/debate › peer-review

Byrd, JC, Smith, S, Wagner-Johnston, N, Sharman, J, Chen, AI, Advani, R, Augustson, B, Marlton, P, Renee Commerford, S, Okrah, K, Liu, L, Murray, E, Penuel, E, Ward, AF & Flinn, IW 2019, 'Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310)', Oncotarget, vol. 10, no. 38, pp. 3827-3830. https://doi.org/10.18632/oncotarget.27011

@article{849b4554afc84224a7cd178c8a0073cf,

title = "Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310)",

abstract = "This article has been corrected: Due to errors in figure preparation, the data for Table 3 was listed incorrectly. It has now been updated with corrected numbers (see text in Table 3) and the resulting graphs (Figure 2A and 2B) have been updated as well. In addition, the reference list for this paper was accidentally alphabetized during the production process, while citation numbers within the article remained according to first-mention. In this correction, the entire references list has been corrected. We include the reference list in their order of mention so that the citation number in the article corresponds to the reference number in the list.(Table Persented).",

author = "Byrd, {John C.} and Stephen Smith and Nina Wagner-Johnston and Jeff Sharman and Chen, {Andy I.} and Ranjana Advani and Bradley Augustson and Paula Marlton and {Renee Commerford}, S. and Kwame Okrah and Lichuan Liu and Elaine Murray and Elicia Penuel and Ward, {Ashley F.} and Flinn, {Ian W.}",

year = "2019",

doi = "10.18632/oncotarget.27011",

language = "English (US)",

volume = "10",

pages = "3827--3830",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "38",

}

TY - JOUR

T1 - Correction

T2 - First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310)

AU - Byrd, John C.

AU - Smith, Stephen

AU - Wagner-Johnston, Nina

AU - Sharman, Jeff

AU - Chen, Andy I.

AU - Advani, Ranjana

AU - Augustson, Bradley

AU - Marlton, Paula

AU - Renee Commerford, S.

AU - Okrah, Kwame

AU - Liu, Lichuan

AU - Murray, Elaine

AU - Penuel, Elicia

AU - Ward, Ashley F.

AU - Flinn, Ian W.

PY - 2019

Y1 - 2019

N2 - This article has been corrected: Due to errors in figure preparation, the data for Table 3 was listed incorrectly. It has now been updated with corrected numbers (see text in Table 3) and the resulting graphs (Figure 2A and 2B) have been updated as well. In addition, the reference list for this paper was accidentally alphabetized during the production process, while citation numbers within the article remained according to first-mention. In this correction, the entire references list has been corrected. We include the reference list in their order of mention so that the citation number in the article corresponds to the reference number in the list.(Table Persented).

AB - This article has been corrected: Due to errors in figure preparation, the data for Table 3 was listed incorrectly. It has now been updated with corrected numbers (see text in Table 3) and the resulting graphs (Figure 2A and 2B) have been updated as well. In addition, the reference list for this paper was accidentally alphabetized during the production process, while citation numbers within the article remained according to first-mention. In this correction, the entire references list has been corrected. We include the reference list in their order of mention so that the citation number in the article corresponds to the reference number in the list.(Table Persented).

UR - http://www.scopus.com/inward/record.url?scp=85066929964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066929964&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.27011

DO - 10.18632/oncotarget.27011

M3 - Comment/debate

C2 - 31217910

AN - SCOPUS:85066929964

SN - 1949-2553

VL - 10

SP - 3827

EP - 3830

JO - Oncotarget

JF - Oncotarget

IS - 38

ER -

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this